Valuation: VolitionRx Limited

Market Cap 3.29M 2.92M 2.74M 2.48M 4.69M 318M 4.72M 32.88M 12.79M 162M 12.37M 12.1M 521M P/E 2026 *
-0.12x
P/E 2027 * -0.23x
Enterprise Value 3.29M 2.92M 2.74M 2.48M 4.69M 318M 4.72M 32.88M 12.79M 162M 12.37M 12.1M 521M EV / Sales 2026 *
1.21x
EV / Sales 2027 * 0.36x
Free-Float
94.07%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week-3.95%
Current month-5.85%
1 month-30.52%
3 months-82.65%
6 months-92.92%
Current year-95.25%
1 week 0.23
Extreme 0.23
0.26
1 month 0.23
Extreme 0.23
0.36
Current year 0.23
Extreme 0.23
7.73
1 year 0.23
Extreme 0.23
13.4
3 years 0.23
Extreme 0.23
24.6
5 years 0.23
Extreme 0.23
82.8
10 years 0.23
Extreme 0.23
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Tax

Executive/Senior Manager

-284 0.0021%
28/09/26 Tax

Chief Operating Officer

-608 0.0045% -
17/03/26
Concord International, Inc.
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+4.70%-3.95%-98.13%-98.26% 3.29M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +0.50%-1.01%+37.48%+103.22% 39.36B
Weighted average by Cap. +0.75%-0.50%+56.58%+134.21%

Financials

2026 *2027 *
Net sales 2.72M 2.42M 2.26M 2.05M 3.87M 263M 3.9M 27.17M 10.57M 134M 10.22M 10M 431M 9.27M 8.23M 7.7M 6.98M 13.19M 894M 13.28M 92.53M 35.99M 456M 34.81M 34.07M 1.47B
Net income -22.25M -19.75M -18.48M -16.75M -31.64M -2.14B -31.87M -222M -86.35M -1.09B -83.52M -81.73M -3.52B -18.42M -16.35M -15.3M -13.87M -26.19M -1.78B -26.38M -184M -71.48M -906M -69.14M -67.65M -2.91B
Net Debt - -
Projected Income Statement - Annual - VolitionRx Limited
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
07/10/26 $0.2429 +4.70% 637,232
05/10/26 $0.2320 -1.28% 716,926
02/10/26 $0.2350 +0.13% 1,381,586
01/10/26 $0.2347 -9.03% 8,137,816
30/09/26 $0.2580 +0.74% 1,444,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - VolitionRx Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2429USD
Average target price
13.62USD
Spread / Average Target
+5,508.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - VolitionRx Limited
  1. Stock Market
  2. Stocks
  3. VNRX Stock